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Introduction. Intradialytic hypotension (IDH) is a common complication during hemodialysis which may increase mortality risks.
Low dose of Korean red ginseng (KRG) has been reported to increase blood pressure. Whether KRG can improve hemodynamic
stability during hemodialysis has not been examined. Methods. The 8-week study consisted of two phases: observation phase
and active treatment phase. According to prehemodialysis blood pressure (BP), 38 patients with IDH were divided into group
A( B P≥ 140/90mmHg, n = 18) and group B (BP < 140/90mmHg, n = 20). Patients were instructed to chew 3.5gm KRG
slices at each hemodialysis session during the 4-week treatment phase. Blood pressure changes, number of sessions disturbed
by symptomatic IDH, plasma levels of vasoconstrictors, blood biochemistry, and adverse eﬀects were recorded. Results.K R G
signiﬁcantly reduced the degree of blood pressure drop during hemodialysis (P<0.05) and the frequency of symptomatic IDH
(P<0.05). More activation of vasoconstrictors (endothelin-1 and angiotensin II) during hemodialysis was found. The postdialytic
levels of endothelin-1 and angiotensin II increased signiﬁcantly (P<0.01). Conclusion. Chewing KRG renders IDH patients better
resistance to acute BP reduction during hemodialysis via activation of vasoconstrictors. Our results suggest that KRG could be an
adjuvant treatment for IDH.
1.Introduction
Intradialytic hypotension (IDH) is a common complication
which occurs in 20–30% of all dialysis treatments [1].It has a
negativeimpactonqualityoflifeduetoassociatedsymptoms
such as nausea, vomiting, dizziness, and cramps. IDH may
cause premature discontinuation of hemodialysis that may
lead to chronic underdialysis and higher mortality risks
[1, 2].
The mechanism responsible for IDH is an inappropriate
response of cardiovascular and neurohormonal systems to
the acute plasma volume removal during dialysis [3–5].
Hemodialysis prescriptions include ultraﬁltration amount,
dialysate composition, and solution temperature may aﬀect
the frequency of IDH [6–8]. Older age, ischemic heart
disease, diabetes, and autonomic neuropathy increase the
risk of developing IDH [9–11]. Common interventions to
prevent IDH include adaptation of dialysis prescriptions,
avoidance of food during dialysis, and administration of
vasoconstrictoragents(e.g.,midorine,adenosineantagonist)
[1, 6, 12–14].
Panax ginseng, a naturally occurring compound that has
beenusedforseveralthousandyearsintheorient[15],isone
of the most popular herbs in the world due to its therapeutic2 Evidence-Based Complementary and Alternative Medicine
eﬀects on modulating immune and cardiovascular functions
[16]. Previous studies on Panax ginseng have conﬁrmed its
eﬀect on regulating blood pressure [15]. Interestingly, Panax
ginseng at low-doses can elevate blood pressure, while high-
dose Panax ginseng has hypotensive eﬀect in healthy subjects
[17–19]. However, the potential therapeutic eﬀect of Panax
ginseng in patients with IDH has not been examined.
Korean red ginseng (KRG), a steamed form of Panax gin-
seng with preserved major constituents, has been shown to
possess more biological activity than Panax ginseng [20–22].
Here we conducted a prospective study to evaluate the eﬀects
of KRG on the occurrence of symptomatic IDH during
hemodialysis. We also examined the changes of endothelin-1
(ET-1), plasma renin activity (PRA), angiotensin II (AngII),
and nitric oxide (NO) products during hemodialysis with
and without oral KRG administration.
2.MaterialandMethods
2.1. Participants. The study was conducted at the hemodial-
ysis center in Taoyuan Chang Gung Memorial Hospital
(TCGMH), Taiwan. The study was approved by Chang Gung
Memorial Hospital Ethical Review Committees. Each patient
signed informed consent before enrollment. Patients aged
from 20- to 80-year-old on thrice-weekly hemodialysis, with
a treatment time of at least 180 minutes, and had at least
three symptomatic episodes of IDH in the 30 days preceding
enrollment, were enrolled in the study. IDH was deﬁned
as a decrease in systolic blood pressure (≥20mmHg) or
ad e c r e a s ei nm e a na r t e r i a lp r e s s u r e( ≥10mmHg) accom-
panied by symptoms (dizziness, cramps, or fatigue, etc.),
according to Kidney Disease Outcomes Quality Initiative
Clinical Practice Guidelines for Cardiovascular Disease in
Dialysis Patients [23]. The exclusion criteria included preg-
nancy or breast feeding, active infectious disease, current
intake of antihypotensive medication or warfarin, and
frequent changes of dry body weight (> ±1% during the
screening phase) and severe medical conditions included
livercirrhosis,heartfailure,autoimmunedisease,andcancer.
Of the 768 patients receiving chronic dialysis in our hospital,
74 patients were eligible for this study; 46 patients were
enrolled, while 28 patients declined to participate (Figure 1).
2.2. Study Design. The prospective study was designed to
evaluate the pre- and posttreatment diﬀerences, and each
patient served as his/her own control. The 8-week study
consisted of two phases: an observation phase (phase I)
and an active treatment phase (phase II). Each phase was
composed of twelve consecutive HD treatments (4 weeks).
PatientsweregivenstandardtreatmentforIDHduringphase
I. These enrolled patients were divided into two groups
according to their prehemodialysis blood pressure. Patients
with average prehemodialysis blood pressure more than
140mmHg systolic or 90mmHg diastolic during phase I
were clustered to group A, while patients with normal or low
prehemodialysis blood pressure to group B.
2.3.Treatment. Duringtheactivetreatmentphase(phaseII),
patients were instructed to chew 3.5 gm KRG slices at each
hemodialysis session. Each slice of KRG was put into the
mouth until melted, then chewed and swallowed. Patients in
group A (hypertensive at baseline) were given KRG slices 60
minutes after the onset of hemodialysis to prevent late onset
of hypotension after ultraﬁltration. In contrast, patients
in group B (normotensive or hypotensive at baseline)
were given KRG slices 30 minutes before hemodialysis to
prevent early onset of hypotension [24]. Cheong-Kwan-Jang
Korean red ginseng (Korea Ginseng Corporation; Korea)
was used in this study. The active constituents of KRG
are ginsenosides including Rb1 (1.96%), Rb2 (2.18%), Rc
(1.47%), Rd (0.72%), Re (1.11%), Rf (0.24%), Rg1 (0.49%),
Rg2 (0.13%), Rg3 (0.12%), Rh1 (0.12%), and Rh2 (0.003%)
[25]. Routine dialysis prescriptions including dialyzer types,
dialysate compositions, dialysate temperature, dialysis fre-
quencies, treatment time, and antihypertensive medications
were maintained constantly throughout two study phases.
2.4. Outcome Parameters. Arterial blood pressure was mea-
sured with an electronic digital sphygmomanometer every
60 minutes from the beginning to the end of each dialysis
session. In the event of IDH, the blood pressure was
checked every 10 minutes. Prehemodialysis (pre-HD), pos-
themodialysis (post-HD), and intradialytic lowest (nadir)
blood pressure at each dialysis session were recorded. The
diﬀerence of SBP, DBP, and MAP between prehemodialysis
and nadir, and between prehemodialysis and posthemodial-
ysis, were calculated. The number of sessions disturbed by
symptomatic IDH was deﬁned as hypotensive episodes that
require medical intervention including transient reduction
or premature stop of ultraﬁltration, infusion of isotonic
or hypertonic saline, or glucose solution. These parameters
during each study phase were recorded by the nurses at the
hemodialysiscenter.Anyadverseeﬀectsthatmightberelated
to KRG were recorded.
2.5. Assays. In the last dialysis sessions of each study phase,
plasma levels of ET-1, PRA, AngII, and NO products
were checked before and after dialysis. Blood samples were
collected with prechilled polypropylene tubes containing
1mg/mL of K2-EDTA and 500KIU/mL aprotinin (Sigma).
Plasma was separated by centrifugation at 3000rpm for 15
minutes at 4◦Ca n ds t o r e da t−70◦C until assayed. Speciﬁc
antibodies and radioimmunoassay kits were used to assay
PRA(DiaSorin,MN,USA),AngII(PhoenixPharmaceuticals
Inc. USA), and ET-1 (Peninsula Laboratories, LLC, USA).
The ﬁnal products of NO metabolism were examined using
an assay for detecting the plasma levels of the nitrate+nitrite
(NT) (Cayman Chemical Company, Ann Arbor). Hemat-
ocrit, albumin, electrolytes, and alanine aminotransferase
were monitored at the beginning and end of the study by
autoanalyzer.
2.6.StatisticalAnalyses. Allnumericalvaluesareexpressedas
mean±standard deviation (SD). Baseline variables are com-
pared with the χ2 test for dichotomous variables. The Mann-
Whitney U test is applied to compare intergroup diﬀeren-
ces. The Wilcoxon signed-rank test is used for intragroupEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Flow chart of patient recruitment. Patients aged from 20 to 80 year old on thrice-weekly hemodialysis, with a treatment time of at
least 180 minutes and had at least three symptomatic episodes of intradialytic hypotension (IDH) in the 30 days preceding enrollment, were
enrolled in the study.
Table 1: Baseline characteristics of study patients.
Total (n = 38) Group A (HTN) (n = 18) Group B (Non-HTN) (n = 20) P value
Age (year) 52.6 ±12.45 6 .2 ±12.74 9 .3 ±11.5 0.083
Sex (% Female) 25 (65.8%) 11 (61.1%) 14 (70%) 0.734
Dry BW (kg) 60.7 ±16.66 2 .5 ±15.05 9 .0 ±18.1 0.515
BMI 23.6 ±5.22 4 .1 ±4.22 3 .1 ±6 0.579
Time on dialysis (months) 93.0 ±61.96 7 .9 ±48.7 115.5 ±64.9 0.016∗
Comorbidities
DM 15 (39.5%) 13 (72.2%) 2 (10%) <0.001∗∗
HTN history 26 (68.4%) 18 (100%) 8 (40%) <0.001∗∗
Previous MI 1 (2.6%) 1 (5.6%) 0 (%) 0.474
Angina history 5 (13.2%) 3 (16.7%) 2 (10%) 0.653
Values are expressed as means ± SD or number (%); BMI, body mass index; BW, body weight; DM, diabetes mellitus; HTN, hypertension; MI, myocardial
infarction; ∗P < 0.05; ∗∗P < 0.01.
comparison between phase I and phase II. A two-tailed P<
0.05 is considered statistically signiﬁcant. Statistical analysis
is performed with analytical Software SPSS 12.0 version.
3. Results
3.1. Patient Characteristics. Of the 46 enrolled patients, 21
patients were grouped into group A and 25 patients to
group B according to prehemodialysis blood pressure in the
observation phase (phase I) (Figure 1). In total, 41 patients
completed the KRG treatment phase (phase II), and ﬁve
patients dropped out of the study prematurely due to poor
compliance (n = 1i ng r o u pA ;n = 2 in group B), catheter
infection (n = 1 in group B), and death due to sepsis and
cerebrovascular accident (n = 1 in group A) which was not
directly related to KRG use. For the statistical analyses, three
patientswereexcludedduetoadjustmentofantihypertensive
medications (n = 1 in group A) and changes of dry weight
exceeding ±1% (n = 2 in group B). Finally, 18 patients in
t h eg r o u pAa n d2 0p a t i e n t si nt h eg r o u pBw e r ei n c l u d e df o r
analysis.
Baseline patient characteristics of the 38 patients of the
analysis population are listed in Table 1. The mean age
was 53 ± 12 years; 25 (65.8%) were females and 13 (34.2%)
were males. Compared to patients in group B (normal
or low prehemodialysis BP), patients in group A (high
prehemodialysis BP) had a signiﬁcantly shorter average time
on maintenance dialysis (68 ± 49 versus 116 ± 65 months,
P = 0.016) and a higher percentage of diabetes mellitus
(72.2% versus 10%, P<0.001).4 Evidence-Based Complementary and Alternative Medicine
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Figure 2:Comparisonofthefrequencyofintradialytichypotension
(IDH) with and without Korean red ginseng (KRG) treatment.
Phase I is the control phase (grey boxes). Phase II is the KRG
treatment phase (white boxes). The number of sessions disturbed
by symptomatic IDH reduced signiﬁcantly after KRG treatment
in both group A (hypertensive at baseline, n = 18, P = 0.016)
and group B (normotensive or hypotensive at baseline, n = 20,
P = 0.035). Data are shown as box and whisker plots. Horizontal
lines represent median values. The boxes encompass the ﬁrst and
3rd quartile of the included data. The bars give the 95% conﬁdence
interval of the values.
∗P < 0.05.
3.2. Eﬀect of KRG on Symptomatic IDH. We examined
the clinical eﬀects of KRG on symptomatic IDH. The
number of sessions disturbed by symptomatic IDH reduced
signiﬁcantly from 3.9 ± 3.1 times (per 12 times) to 2.7 ± 3.1
t i m e si ng r o u pA( P = 0.016) and from 3.9 ± 3.9t i m e s
to 2.7 ± 3.5 times in group B (P = 0.035) (Figure 2). The
average pre- and postdialysis body weight, dry weight, and
the amount of actual ultraﬁltration were not signiﬁcantly
diﬀerent between two study phases (Table 2). Thus, we could
excludetheeﬀectofalteredultraﬁltrationamountthatmight
have aﬀected the occurrence of IDH.
3.3. Eﬀect of KRG on Blood Pressure during Hemodialysis. We
looked at the eﬀects of KRG in regulating the blood pressure
changes during hemodialysis (Table 3). We found that the
nadir SBP in group B was signiﬁcantly elevated from 76.3 ±
16.2mmHg in phase I to 79.1 ±15.8mmHg in phase II (P =
0.045). A similar trend of increased nadir SBP was noted in
group A (97.4±16.0i np h a s eIv e r s u s1 0 0 .1 ± 18.6i np h a s e
II; P = 0.184). However, the administration of KRG did not
signiﬁcantly change prehemodialysis or posthemodialysis
blood pressure.
Furthermore, we calculated the diﬀerences of blood
pressure measured at diﬀerent time points (prehemodialysis
to nadir and to posthemodialysis) (Table 4). Notably, we
found that patients in group B experienced less blood
pressure changes during phase II (−24.4 ± 10.1mmHg of
Nadir-Pre SBP in phase I to −20.4 ± 11.0mmHg in phase II,
P = 0.045; −13.2±7.1mmHgofnadir-pre-DBPinphaseIto
−10.4±6.6mmHginphaseII,P = 0.011; −16.9±7.1mmHg
of nadir-pre-MAP in phase I to −13.8 ± 7.7mmHg in phase
II, P = 0.015; −11.0 ± 6.3mmHg to −7.8 ± 6.3mmHg in
post-pre-DBP, P = 0.025). A similar trend was also noted in
groupAafterKRGtreatment(−50.7 ± 39.3mmHg of nadir-
pre-SBP in phase I to −42.0 ± 23.8mmHg in phase II, P =
0.053; −40.3 ± 39.3mmHg of nadir-pre-MAP in phase I to
−31.8±24.8mmHg in phase II, P = 0.02). When all patients
were included for analysis, the blood pressure drop reduced
signiﬁcantly in the KRG-treated period (−36.9±30.7mmHg
of nadir-pre-SBP in phase I to −31.0 ± 21.3mmHg in phase
II, P = 0.006; −22.4 ± 14.5mmHg of nadir-pre-MAP in
p h a s eIt o−19.3±12.7mmHg in phase II, P = 0.004). These
results indicate that KRG may help to keep hemodynamic
stability in IDH patients.
3.4. Eﬀect of KRG on PRA, ET-1, AngII, and NT. To investi-
gate the action mechanism of KRG, we examined the plasma
levels of PRA, ET-1, AngII, and NT (nitrite + nitrate).
In the observation phase (phase I), PRA levels increased
signiﬁcantly after hemodialysis in group B (P = 0.004) but
less evident in group A (P = 0.071). The level of ET-1
and AngII did not signiﬁcantly increase despite an average
ultraﬁltration of 2.6 ± 1.0kg with removal of ﬂuid in both
groups (P>0.05).
After four weeks of KRG treatment (phase II), the
posthemodialysis PRA levels increased signiﬁcantly in both
groups (P = 0.005 in group A, P<0.001 in group
B) (Figure 3). Similarly, the posthemodialysis ET-1 levels
increased signiﬁcantly by one- to threefold compared to
the prehemodialysis levels (P = 0.035 in group A, P =
0.011 in group B), which is in contrast to the trend in
phase I (Figure 3). The levels of AngII also signiﬁcantly
increased after dialysis in group A (P = 0.033), but not
in group B (P = 1.000). A previous study has shown
that NT can be removed by hemodialysis [4]. As expected,
the levels of NT decreased signiﬁcantly after dialysis in all
groups. Nevertheless, the posthemodialysis NT levels which
would cause vasodilation were signiﬁcantly lower in the
KRG treatment phase than those in the observatory phase
(P<0.05 in group A) (Figure 3). These results suggest that
KRG treatment may improve the compensatory response
mediatedbyvariousvasoconstrictorstoacutevolumechange
during hemodialysis.
Unexpectedly, we observed a two- to threefold declina-
t i o no fp r e h e m o d i a l y s i sE T - 1l ev e l si nb o t hgr o u p swi t hK R G
treatment (1.627±1.460 to 0.497±0.202ng/mL in group A,
P = 0.014; 2.042 ± 1.127 to 1.023 ± 1.190ng/mL in group
B, P = 0.047) as shown in Figure 3. The same holds trueEvidence-Based Complementary and Alternative Medicine 5
Table 2: Comparison of body weights and ultraﬁltration rates with and without Korean red ginseng treatment.
Group A (HTN)
P value
Group B (non-HTN)
P value
All
P value
Phase I
(−KRG)
Phase II
(+KRG)
Phase I
(−KRG)
Phase II
(+KRG)
Phase I
(−KRG)
Phase II
(+KRG)
BW predialysis (Kg) 65.3 ± 15.56 5 .4 ±15.4 0.862 61.6 ±18.86 1 .7 ±18.8 0.218 63.4 ±17.26 3 .4 ±17.1 0.415
BW postdialysis (Kg) 62.7 ± 15.06 2 .8 ±15.0 0.296 59.0 ±18.15 8 .9 ±18.1 0.888 60.7 ±16.66 0 .7 ±16.6 0.994
Dry BW (Kg) 62.5 ± 15.06 2 .6 ±15.0 0.054 59.0 ±18.15 9 .0 ±18.2 0.386 60.7 ±16.66 0 .7 ±16.6 0.282
Target UF (L) 2.6 ± 1.02 .6 ±0.9 0.616 2.7 ±1.02 .8 ±1.1 0.322 2.6 ±1.02 .7 ±1.00 . 3 3
Actual UF (L) 2.8 ± 1.12 .7 ±1.0 0.850 2.7 ±1.13 .0 ±1.6 0.198 2.7 ±1.12 .9 ±1.4 0.338
%t a r g e tU F 100.0 ±21.5 106.4 ±39.1 0.231 103.8 ±10.4 103.0 ±10.6 0.794 102.0 ±16.5 104.6 ±27.6 0.319
Values are expressed as means ± SD; BW, body weight; KRG, Korean red ginseng; UF, ultraﬁltration; % target UF, percentage of actual UF/target UF. Phase I
is the controlled phase without KRG treatment, expressed as −KRG; phase II is the KRG treatment phase, expressed as +KRG.
Table 3: Comparison of blood pressure measurements during hemodialysis with and without Korean red ginseng treatment.
Group A (HTN) P value Group B (non-HTN) P value
Phase I (−KRG) Phase II (+KRG) Phase I (−KRG) Phase II (+KRG)
Pre- SBP (mmHg) 148.1 ±39.3 142.9 ±30.8 0.231 100.8 ±16.99 9 .5 ±14.5 0.332
Pre-DBP (mmHg) 71.1 ±10.47 1 .3 ±13.0 0.931 58.2 ±9.75 6 .8 ±8.1 0.279
Pre-MAP (mmHg) 96.8 ±18.79 5 .2 ±18.5 0.327 72.4 ±11.97 1 .0 ±9.9 0.218
Nadir SBP (mmHg) 97.4 ±16.0 100.1 ±18.6 0.184 76.3 ±16.27 9 .1 ±15.8 0.045a
Nadir DBP (mmHg) 53.9 ±8.45 4 .8 ±9.4 0.338 45.0 ±9.84 6 .4 ±10.3 0.341
Nadir MAP (mmHg) 68.4 ±10.46 9 .9 ±11.9 0.231 55.5 ±11.85 7 .2 ±12.02 0.296
Post-SBP (mmHg) 107.8 ±17.2 111.1 ±17.2 0.053 86.7 ±30.98 4 .8 ±16.4 0.305
Post-DBP (mmHg) 58.4 ±8.75 9 .0 ±8.8 0.396 47.2 ±10.14 9 .0 ±10.9 0.135
Post-MAP (mmHg) 74.9 ±10.77 6 .4 ±11.1 0.248 60.3 ±16.36 1 ±12.3 0.284
Values are expressed as means ± SD of the data; KRG: Korean red ginseng; pre-: prehemodialysis; post-: posthemodialysis; SBP: systolic blood pressure; DBP:
diastolic blood pressure; MAP: mean arterial pressure; aP<0.05.
Table 4: Changes of blood pressure during hemodialysis with and without Korean red ginseng treatment.
Group A (HTN)
P value
Group B (non-HTN)
P value
All
P value
Phase I
(−KRG)
Phase II
(+KRG)
Phase I
(−KRG)
Phase II
(+KRG)
Phase I
(−KRG)
Phase II
(+KRG)
ΔNadir-pre-SBP (mmHg) −50.7±39.3 −42.9±23.8 0.053 −24.4±10.1 −20.4±11.0 0.045∗ −36.9±30.7 −31.0±21.3 0.006∗∗
ΔNadir-pre-DBP (mmHg) −17.3 ±8.8 −16.6±10.0 0.446 −13.2 ±6.2 −10.4 ±6.6 0.011∗ −15.1 ±7.7 −13.3 ±8.8 0.020∗
ΔNadir-pre-MAP (mmHg) −28.4±18.0 −25.4±14.4 0.078 −16.9 ±7.1 −13.8 ±7.7 0.015∗ −22.4±14.5 −19.3±12.7 0.004∗∗
ΔPost-preSBP (mmHg) −40.3±39.3 −31.8±24.8 0.020∗ −14.1±23.4 −14.7 ±9.9 0.232 −26.5±34.2 −22.8±20.2 0.011∗
ΔPost-preDBP (mmHg) −12.7±10.1 −12.3±10.3 0.408 −11.0 ±6.3 −7.8 ±6.3 0.025∗ −11.8 ±8.2 −10.0 ±8.6 0.027∗
ΔPost-preMAP (mmHg) −21.9±18.6 −18.8±14.9 0.048∗ −12.0±10.3 −10.1 ±7.1 0.145 −16.7±15.4 −14.2±12.1 0.014∗
Values are expressed as means ± SD of the data.
Pre-: prehemodialysis; post-: posthemodialysis; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure;
∗P < 0.05; ∗∗P < 0.01; Δ: changes.6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Changes of endotheline-1 (ET-1), plasma renin activity (PRA), angiotensin II (AngII), and NT (Nitrate+nitrite) plasma levels
after KRG treatment in patients with intradialytic hypotension. Phase I is the control phase, and phase II is the KRG treatment phase. The
ET-1 levels increased signiﬁcantly after hemodialysis in phase II in both group A (hypertensive at baseline, n = 18, P = 0.035) and group B
(normotensive or hypotensive at baseline, n = 20, P = 0.011). The posthemodialysis PRA levels increased signiﬁcantly in phase II in both
group A (P = 0.005) and group B (P<0.001). In group A, the AngII levels signiﬁcantly elevated after KRG treatment (P = 0.033). The
levels of NT decreased signiﬁcantly after dialysis in all groups in both phases (P<0.0001). In group A, the posthemodialysis NT level was
signiﬁcantly lower in phase II than those in phase I (P = 0.028).
∗P < 0.05;
∗∗P < 0.01; aP<0.05; aaP<0.01.
for the comparison of prehemodialysis AngII levels between
two phases (3.902 ± 3.162 to 0.477 ± 0.353ng/mL in group
A, P<0.001; 1.616 ± 1.387 to 0.694 ± 0.859ng/mL in
group B, P<0.001). In contrast, the predialysis PRA levels
remained unchanged in the group A but elevated in group B
(P = 0.012) with KRG treatment. There were no signiﬁcant
changes in the prehemodialysis NT levels during the two
study phases.
3.5. Side Eﬀects. No signiﬁcant adverse eﬀects were observed
during the study. Side eﬀects reported by patients were
palpitation (n = 1i ng r o u pA ;n = 1 in group B) and
thirsty (n = 1 in group B). Serum potassium levels increased
slightly from 4.3 ± 0.5t o4 .6 ± 0.7mEq/L(P = 0.016) in
group B with KRG administration, but the diﬀerence were
not signiﬁcant when data from both groups was pooled
(4.4 ± 0.8v e r s u s4 .6 ± 0.7mEq/L, P = 0.189) (Table 5).
Serum phosphate levels were slightly elevated from 4.9 ± 1.4
to 5.3 ± 1.6mg/dL(P = 0.04) with KRG treatment, but the
levels were still within the normal range. No other signiﬁcant
changes in hematologic or biochemical parameters were
observed (Table 5).
4. Discussion
The current treatments for IDH include stopping ultraﬁl-
tration, increasing dialysate sodium and glucose concen-
trations, and administration of hypertonic solutions and
vasoconstrictor agents [1, 6, 12–14]. In the current study,
we found that taking 3.5g KRG slices at the start of
hemodialysiscanelevatethenadirbloodpressureandreduce
the frequency of symptomatic IDH by increasing the nadir
blood pressure. KRG had no signiﬁcant eﬀects on the
baseline blood pressure, suggesting that its beneﬁcial eﬀectEvidence-Based Complementary and Alternative Medicine 7
Table 5: Comparison of laboratory parameters with and without Korean red ginseng treatment.
Group A (HTN)
P value
Group B (non-HTN)
P value
All
P value
Phase I
(−KRG)
Phase II
(+KRG)
Phase I
(−KRG)
Phase II
(+KRG)
Phase I
(−KRG)
Phase II
(+KRG)
Hct (%) 32.5 ±3.63 3 .2 ±3.3 0.170 33.3 ±3.23 2 .9 ±3.6 0.537 32.9 ±3.43 3 .0 ±3.4 0.795
Hb (g/dL) 10.7 ±1.11 0 .8 ±1.0 0.276 10.6 ±1.11 0 .5 ±1.2 0.359 10.7 ±1.11 0 .6 ±1.1 0.849
Ca (mg/dL) 9.7 ±1.39 .6 ±0.8 0.938 10.1 ±1.11 0 .1 ±1.2 0.618 9.9 ±1.29 .8 ±1.0 0.543
P (mg/dL) 5.0 ±1.75 .6 ±1.9 0.065 4.8 ±1.05 .1 ± 1.3 0.360 4.9 ±1.45 .3 ±1.60 . 0 4 ∗
K( m E q / L ) 4.5 ±1.04 .5 ±0.7 0.796 4.3 ±0.54 .6 ± 0.7 0.016∗ 4.4 ±0.84 .6 ±0.7 0.189
BUN (mg/dL) 63.4 ±22.16 4 .3 ±19.2 0.943 58.0 ±11.06 2 .2 ±14.9 0.083 60.5 ±17.26 3 .2 ±16.9 0.186
Cr (mg/dL) 10.1 ±2.91 0 .0 ±2.7 0.523 11.3 ±1.91 1 .3 ±2.2 0.985 10.7 ±2.41 0 .7 ±2.5 0.768
ALT (U/L) 16.2 ±10.01 4 .7 ±7.7 0.459 15.0 ±6.21 3 .8 ±3.9 0.599 15.6 ±8.11 4 .2 ±5.9 0.183
Values are expressed as means ± SD of the data.
Hct: hematocrit; Hb: hemoglobin; Ca: calcium; P: phosphate; K: potassium.
BUN: blood urea nitrogen; Cr: creatinine; ALT: alanine aminotransferase.
∗P < 0.05; ∗∗P < 0.01.
is through restoring the vasoconstrictive response to acute
plasma changes during hemodialysis. Furthermore, KRG has
been used in diﬀerent pathologic conditions [15], and its
safety proﬁle has been well studied in patients with normal
renal function [16]. Our results conﬁrmed the safety of
using oral form KRG during hemodialysis. Although KRG
has been reported to increase blood pressure in non-dialysis
patients [17–19, 26, 27], we did not observe exacerbation
of preexisting hypertension in our patients (group A). Our
results suggest that KRG may be an alternative and adjuvant
treatment for IDH.
The eﬀects of Panax ginseng on regulating blood pres-
sure were controversial due to its complexity of major
components and diﬀerent actions in various pathological
conditions [18, 19, 22, 28, 29]. It has been reported that
dammarenetriol glycosides in Panax ginseng have strong
CNS excitatory actions that may cause hypertension, while
dammarenediol glycosides in Panax ginseng have sedative
and antihypertensive eﬀects [26]. Three decades ago, Siegel
proposed that low-dose Panax ginseng could cause hyper-
tension [18]. However, high-dose Panax ginseng was shown
to increase NO production in recent clinical trials and
laboratory experiments [29], which may reduce blood pres-
sure [28, 30]. Furthermore, Panax ginseng induced diﬀerent
responses in diﬀerent blood vessels taken from rabbits, dogs
and humans qualitatively and quantitatively [31]. Our data
suggest that low-dose KRG (3.5gm per dialysis session)
could maintain the stability of blood pressure rather than
exacerbating hypotension during hemodialysis.
The mechanism of IDH has been partly attributed
to endothelial dysfunction in response to hemodynamic
instability, with increased NO and decreased ET-1 during
hemodialysis [4, 32–34]. ET-1 is the most potent vasocon-
strictor that is locally produced from vascular endothelial
cell [35, 36]. ET-1 levels decrease in IDH prone patients
and increase in patients who have hypertension during
hemodialysis, implying its importance in regulating hemo-
dynamic stability [4]. Consistently, we did not found a
signiﬁcant increase of ET-1 levels during hemodialysis
in these hypotension-prone patients during the observa-
tion period, suggesting a lack of adequate vasoconstrictive
response. Indeed, we detected a signiﬁcant increase in ET-
1 levels during hemodialysis after KRG treatment. Similarly,
we found that KRG treatment led to more activation of
PRA and AngII during hemodialysis, indicating a gradually
restoration of neurohormonal and cardiovascular responses
toacuteplasmavolumechange.AlthoughNTconcentrations
is an indirect measurement of NO and can be removed
by dialysis [4], we observed a signiﬁcant decrease in the
posthemodialysis NT levels after KRG treatment (group
A). The result suggested that the beneﬁcial eﬀects of KRG
treatment on IDH may be partially due to decreased NO
production.
Previous studies have shown that hypotension-prone
patients have higher baseline AngII levels compared to
hypotension resistant dialysis patients [37]. This indicates
that renin-angiotensin-aldosterone system may be abnor-
mally activated in patients with recurrent IDH but still
incapable to have adequate cardiovascular capacitance to
the dialytic ultraﬁltration. Elevation of AngII may lead to
endothelial dysfunction and increase the risk of adverse
cardiovascular events [38]. In the current study, we found
thatKRGtreatmentresultedinsigniﬁcantlyreducedbaseline
AngII and ET-1. Our data suggest that KRG may have
additional beneﬁcial eﬀects on endothelial dysfunction in
patientswithIDHbyloweringthebaselineofET-1andAngII
levels [36, 39].
Despite the promising results obtained in this trial,
several limitations should be acknowledged. First, the study
had a relative small sample size, and further studies are8 Evidence-Based Complementary and Alternative Medicine
needed to conﬁrm the results. Second, the study is a phase I
pilot study, and we could only observe the diﬀerences within
the same patient although this also help to eliminate the
variationofbloodpressurechangesamongdiﬀerentpatients.
Third, the long-term eﬀects of KRG in hemodialysis patients
were not studied, and further investigations are warranted.
5. Conclusions
Chewing low-dose KRG renders patients better resistance
to acute BP reduction during hemodialysis. KRG treatment
improvesthecompensatoryresponsetoacutevolumechange
during hemodialysis via activation of vasoconstrictors (ET-
1 and AngII). Our results suggest that KRG could be an
adjuvant treatment for IDH.
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